Phaseline

Companies › Prelude Therapeutics

Prelude Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PRT12396–Phase 1Polycythemia Vera (PV)Apr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07469891PRT12396Phase 1Polycythemia Vera (PV)OncologyApr 2028

From the company's SEC filings

Cash and short-term investments of $152m on 2026-06-30; operating cash outflow about $76m a year; runway about 24 months at that burn, to Jul 2028

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.